Recombinant Anti-IRF3 (phospho S386) antibody [EPR2346] (ab76493)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2346] to IRF3 (phospho S386)
- Suitable for: WB, Dot blot
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-IRF3 (phospho S386) antibody [EPR2346]
See all IRF3 primary antibodies -
Description
Rabbit monoclonal [EPR2346] to IRF3 (phospho S386) -
Host species
Rabbit -
Tested applications
Suitable for: WB, Dot blotmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide corresponding to Human IRF3 (phospho S386).
Database link: Q14653 -
Positive control
- WB: MCF7 cells treated with Calyculin A.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR2346 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Assay kits
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab76493 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/1000 - 1/10000. Predicted molecular weight: 47 kDa.
|
Dot blot |
1/1000.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 47 kDa. |
Dot blot
1/1000. |
Target
-
Function
Mediates interferon-stimulated response element (ISRE) promoter activation. Functions as a molecular switch for antiviral activity. DsRNA generated during the course of an viral infection leads to IRF3 phosphorylation on the C-terminal serine/threonine cluster. This induces a conformational change, leading to its dimerization, nuclear localization and association with CREB binding protein (CREBBP) to form dsRNA-activated factor 1 (DRAF1), a complex which activates the transcription of genes under the control of ISRE. The complex binds to the IE and PRDIII regions on the IFN-alpha and IFN-beta promoters respectively. IRF-3 does not have any transcription activation domains. -
Tissue specificity
Expressed constitutively in a variety of tissues. -
Sequence similarities
Belongs to the IRF family.
Contains 1 IRF tryptophan pentad repeat DNA-binding domain. -
Post-translational
modificationsConstitutively phosphorylated on many serines residues. C-terminal serine/threonine cluster is phosphorylated in response of induction by IKBKE and TBK1. Ser-385 and Ser-386 may be specifically phosphorylated in response to induction. An alternate model propose that the five serine/threonine residues between 396 and 405 are phosphorylated in response to a viral infection. Phosphorylation, and subsequent activation of IRF3 is inhibited by vaccinia virus protein E3.
Ubiquitinated; ubiquitination involves RBCK1 leading to proteasomal degradation. Polyubiquitinated; ubiquitination involves TRIM21 leading to proteasomal degradation.
ISGylated by HERC5 resulting in sustained IRF3 activation and in the inhibition of IRF3 ubiquitination by disrupting PIN1 binding. The phosphorylation state of IRF3 does not alter ISGylation. -
Cellular localization
Cytoplasm. Nucleus. Shuttles between cytoplasmic and nuclear compartments, with export being the prevailing effect. When activated, IRF3 interaction with CREBBP prevents its export to the cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 3661 Human
- Omim: 603734 Human
- SwissProt: Q14653 Human
- Unigene: 289052 Human
- Unigene: 75254 Human
-
Alternative names
- IIAE7 antibody
- Interferon regulatory factor 3 antibody
- IRF 3 antibody
see all
Images
-
All lanes : Anti-IRF3 (phospho S386) antibody [EPR2346] (ab76493) at 0.2 µg/ml (purified)
Lane 1 : MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysates
Lane 2 : MCF7 (Human breast adenocarcinoma epithelial cell) treated with calyculin A for 45 minutes whole cell lysates
Lane 3 : MCF7 (Human breast adenocarcinoma epithelial cell) treated with calyculin A for 45 minutes whole cell lysates. Then the membrane was incubated with phosphatase
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 47 kDaBlocking and diluting buffer: 5% NFDM/TBST
We are unsure to define the extra band at 37KD.
-
All lanes : Anti-IRF3 (phospho S386) antibody [EPR2346] (ab76493) at 1/20000 dilution (Unpurified)
Lane 1 : MCF7 cell lysate - treated with Calyculin A
Lane 2 : MCF7 cell lysate – untreated
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)
Predicted band size: 47 kDaBlocking buffer - 5% NFDM/TBST
Diluting buffer - 1% BSA
-
Dot blot analysis of IRF3 single phospho peptide pS386 (lane 1) and IRF3 non-phospho peptide (lane 2) with unpurified ab76493 at 1/1000. Blocking and diluting buffer was 5% NFDM/TBST. The secondary antibody used was ab97051 Peroxidase conjugated Goat Anti-Rabbit IgG, (H+L) at 1/100,000.
Datasheets and documents
-
SDS download
-
Datasheet download
References (140)
ab76493 has been referenced in 140 publications.
- Tan J et al. Proteomics analysis uncovers plasminogen activator PLAU as a target of the STING pathway for suppression of cancer cell migration and invasion. J Biol Chem 299:102779 (2023). PubMed: 36496076
- Chen Q et al. Truncated PARP1 mediates ADP-ribosylation of RNA polymerase III for apoptosis. Cell Discov 8:3 (2022). PubMed: 35039483
- Groelly FJ et al. Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours. EMBO Mol Med 14:e14501 (2022). PubMed: 35107878
- Malikov V et al. FEZ1 phosphorylation regulates HSPA8 localization and interferon-stimulated gene expression. Cell Rep 38:110396 (2022). PubMed: 35172151
- Pallett MA et al. DDX50 Is a Viral Restriction Factor That Enhances IRF3 Activation. Viruses 14:N/A (2022). PubMed: 35215908